The reason for the dip appears to be related to Intrexon’s acquisition of GenVec On Jan. 24, Intrexon announced an all-stock deal to acquire GenVec, a wholly clinical-stage company that’s developing the AdenoVerse gene delivery technology, for roughly $7 per share. GenVec stockholders are set to receive 0.297 shares of Intrexon for each share of GenVec that they own, valuing GenVec near $15 million.